John W Shiver

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
  2. ncbi request reprint Development of stable liquid formulations for adenovirus-based vaccines
    Robert K Evans
    Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78 302, Sumneytown Pike, West Point, PA 19486, USA
    J Pharm Sci 93:2458-75. 2004
  3. pmc Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
    Danilo R Casimiro
    Department of Vaccines and Biologics Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 79:15547-55. 2005
  4. ncbi request reprint Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors
    John W Shiver
    Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Annu Rev Med 55:355-72. 2004
  5. pmc Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
    Xiaoping Liang
    Merck Research Laboratories, P O Box 4, WP16 306, West Point, PA 19486, USA
    J Virol 79:12321-31. 2005
  6. ncbi request reprint The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P
    Zhi qiang Zhang
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, PA 19486, USA
    Virology 320:75-84. 2004
  7. ncbi request reprint Evaluation of cellular immune responses in subjects chronically infected with HIV type 1
    Tong Ming Fu
    Merck Research Laboratories, West Point, PA 19486, USA
    AIDS Res Hum Retroviruses 23:67-76. 2007
  8. doi request reprint Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus
    Tong Ming Fu
    Department of Vaccine Basic Research, West Point, PA 19002, USA
    Virology 385:218-26. 2009
  9. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
  10. ncbi request reprint Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection
    Zhi qiang Zhang
    Department of Vaccines and Biologics Research, Merck Research Laboratories, West Point, PA 19486, USA
    Virology 361:455-64. 2007

Detail Information

Publications59

  1. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    ..The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine...
  2. ncbi request reprint Development of stable liquid formulations for adenovirus-based vaccines
    Robert K Evans
    Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78 302, Sumneytown Pike, West Point, PA 19486, USA
    J Pharm Sci 93:2458-75. 2004
    ..The identification of 4 degrees C stable liquid formulations should significantly enhance the utility of Ad5 as a vector for vaccines and gene therapy...
  3. pmc Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
    Danilo R Casimiro
    Department of Vaccines and Biologics Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 79:15547-55. 2005
    ..However, virus control was short-lived, and indications of viral escape were evident as early as 6 months postinfection. The implications of these results in vaccine design and clinical testing are discussed...
  4. ncbi request reprint Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors
    John W Shiver
    Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Annu Rev Med 55:355-72. 2004
    ..Such data, coupled with epidemiology studies that identify HIV-1 gag, pol, and nef as the best antigens for broadly directed cellular immune responses, provide guidance for the development of a potential AIDS vaccine...
  5. pmc Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
    Xiaoping Liang
    Merck Research Laboratories, P O Box 4, WP16 306, West Point, PA 19486, USA
    J Virol 79:12321-31. 2005
    ..The implications of these results in the development of an HIV-1 vaccine will be discussed...
  6. ncbi request reprint The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P
    Zhi qiang Zhang
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, PA 19486, USA
    Virology 320:75-84. 2004
    ....
  7. ncbi request reprint Evaluation of cellular immune responses in subjects chronically infected with HIV type 1
    Tong Ming Fu
    Merck Research Laboratories, West Point, PA 19486, USA
    AIDS Res Hum Retroviruses 23:67-76. 2007
    ..Our findings suggest that the high levels of ELISpot responses in chronically infected subjects were reflective of their persistent viral infection...
  8. doi request reprint Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus
    Tong Ming Fu
    Department of Vaccine Basic Research, West Point, PA 19002, USA
    Virology 385:218-26. 2009
    ..The implications of these results in antiviral mechanisms of immune responses induced by M2 vaccines are discussed...
  9. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
    ....
  10. ncbi request reprint Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection
    Zhi qiang Zhang
    Department of Vaccines and Biologics Research, Merck Research Laboratories, West Point, PA 19486, USA
    Virology 361:455-64. 2007
    ....
  11. ncbi request reprint Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay
    Sheri Dubey
    Department of Vaccine and Biologics Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Acquir Immune Defic Syndr 45:20-7. 2007
    ....
  12. doi request reprint Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates
    Adam J Simon
    Department of Alzheimer s Research, Merck Research Laboratories, West Point, PA 19486, USA
    Vaccine 26:5202-9. 2008
    ..Compared to an efficient viral Ad5 vector system, the gene expression levels of DNA+electrostimulation were surprisingly within a factor of four of the viral delivery system...
  13. pmc Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge
    Danilo R Casimiro
    Department of Vaccines Basic Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 84:2996-3003. 2010
    ..The implications of these results in light of the recent discouraging results of the phase IIb study of the trivalent Ad5 HIV-1 vaccine are discussed...
  14. ncbi request reprint Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC
    Lisa S Kierstead
    Vaccine and Biologics Research, Merck Research Laboratories, West Point and Wayne, PA 19087, USA
    AIDS Res Hum Retroviruses 23:86-92. 2007
    ..These studies establish the importance of optimal conditions for PBMC collection and handling to the success of a clinical development program...
  15. pmc DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles
    Kara S Cox
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Virol 82:8161-71. 2008
    ..Implications of these results for future vaccine development will be discussed...
  16. ncbi request reprint PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination
    Adam C Finnefrock
    Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Immunol 182:980-7. 2009
    ..05) increase in the peak percentage of T cells specific for the CM9 Gag epitope. These new results on PD-1 blockade in nonhuman primates point to a broader role for PD-1 immunomodulation and to potential applications in humans...
  17. doi request reprint Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys
    Tong Ming Fu
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486, United States
    Vaccine 27:1440-7. 2009
    ..Surprisingly, HBVc expressing M2 peptide was an inferior vaccine in rhesus monkeys, whether as a primary vaccine or as a booster vaccine, when compared with M2-OMPC conjugate vaccine...
  18. ncbi request reprint Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques
    Daria J Hazuda
    Department of Biological Chemistry, Merck Research Laboratories, Post Office Box 4, West Point, PA 19486, USA
    Science 305:528-32. 2004
    ..These studies demonstrate integrase inhibitor activity in vivo and suggest that cellular immunity facilitates chemotherapeutic efficacy in retroviral infections...
  19. pmc Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Virol 77:7663-8. 2003
    ..The implications of these results are discussed...
  20. doi request reprint Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans
    Andrew J Bett
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486 0004, USA
    Vaccine 28:7881-9. 2010
    ....
  21. ncbi request reprint Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys
    Jiang Fan
    Department of Vaccine and Biologics Research, Merck Research Laboratories, 770 Sumneytown Pike, P O Box 4, WP16 306, West Point, PA 19486, USA
    Vaccine 22:2993-3003. 2004
    ..The data presented here will permit better understanding of the potential of an M2-based vaccine approach...
  22. ncbi request reprint Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines
    Miguel Aste-Amezaga
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Co, Inc, West Point, PA 19486, USA
    Hum Gene Ther 15:293-304. 2004
    ..The evaluation of serotype-specific neutralizing antibodies can be of both clinical and epidemiologic importance as a means of selecting the appropriate serotype adenovector(s)...
  23. pmc Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection
    Zhi qiang Zhang
    Department of Viral Vaccine Research, Merck Research Laboratories, 770 Sumneytown Pike, PO Box 4, WP16 225, West Point, PA 19486, USA
    J Virol 76:12845-54. 2002
    ..These data indicate that MHC class I allele-restricted CTL responses may play an important role in preservation of lymphoid tissue structure, thereby resulting in attenuation of disease progression in immunodeficiency virus infection...
  24. ncbi request reprint Progress towards the development of a HIV-1 gp41-directed vaccine
    Georgia B McGaughey
    Department of Molecular Systems, Merck Research Laboratories, P O Box 4, West Point, PA 19486, USA
    Curr HIV Res 2:193-204. 2004
    ..The implication of these findings with regard to structural and immunological considerations is discussed...
  25. ncbi request reprint HIV type 1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses
    Adam C Finnefrock
    Vaccine and Biologics Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 23:1283-92. 2007
    ..For more diverse proteins, adding a second strain can add a significant increase in breadth, although for three or more strains the intrinsic diversity of the protein leads to diminishing improvement...
  26. ncbi request reprint A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects
    Timothy W Tobery
    Department of Vaccines and Biologics Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 22:1081-90. 2006
    ....
  27. pmc Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine
    Daniel C Freed
    Department of Vaccines Research, Merck Research Laboratories, West Point, PA 19486
    Proc Natl Acad Sci U S A 110:E4997-5005. 2013
    ..Importantly, potent neutralizing mAbs reacted to the pentameric gH complex but not to gB. Thus, the pentameric gH complex is the primary target for antiviral antibodies by vaccination. ..
  28. doi request reprint Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus
    Tong Ming Fu
    Department of Vaccines Research, Merck Research Laboratories, West Point, PA, United States
    Vaccine 30:7469-74. 2012
    ....
  29. ncbi request reprint Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice
    Xaioping Liang
    Merck Research Laboratories, Department of Virus and Cell Biology, Merck and Co Inc, Sumneytown Pike, P O Box 4, West Point, PA 19486, USA
    Vaccine 20:3413-21. 2002
    ..These findings may have practical implications for developing HIV-1 Nef vaccine component...
  30. ncbi request reprint A replication-defective human cytomegalovirus vaccine for prevention of congenital infection
    Dai Wang
    Merck Research Laboratories, Merck and Co Inc, Kenilworth, NJ 07033, USA
    Sci Transl Med 8:362ra145. 2016
    ..The vaccine was immunogenic in multiple animal species and induced durable neutralizing antibodies, as well as CD4+ and CD8+ T cells, to multiple viral antigens in nonhuman primates...
  31. pmc An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions
    Joseph G Joyce
    Department of Vaccines Basic Research, Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA 19486, USA
    Proc Natl Acad Sci U S A 105:15684-9. 2008
    ....
  32. doi request reprint International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials
    T Christopher Mast
    Merck Research Laboratories, West Point, PA, USA christopher
    Vaccine 28:950-7. 2010
    ..Coincident Ad5/6 titers were lower than either Ad5 or Ad6 titers alone. Understanding pre-existing immunity to candidate vaccine vectors may contribute to the evaluation of vaccines in international populations...
  33. pmc A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
    Michael D Miller
    Department of Antiviral Research, Merck Research Laboratories, West Point, PA 19486, USA
    Proc Natl Acad Sci U S A 102:14759-64. 2005
    ..Our data provide a structural framework for the design of new immunogens and therapeutic antibodies with crossneutralizing potential...
  34. ncbi request reprint Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses
    Rima Youil
    Merck and Company, West Point, PA 19486, USA
    Hum Gene Ther 14:1017-34. 2003
    ..This increased robustness will be critical when adapting first-generation recombinant adenovectors to commercial production...
  35. ncbi request reprint Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines
    Robert K Evans
    Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78 302, Sumneytown Pike, West Point, Pennsylvania 19486, USA
    J Pharm Sci 93:1924-39. 2004
    ..These results indicate that the addition of BAK to DNA/CRL1005 formulations leads to the formation of approximately 300 nm CRL1005-BAK-DNA particles that enhance the cellular immune response in rhesus monkeys...
  36. ncbi request reprint Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens
    Fubao Wang
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Co, Inc West Point, PA 19486, USA
    Hum Gene Ther 14:25-36. 2003
    ..This assay may be used for clinical trials using adenovirus vectors as vehicles for vaccines...
  37. ncbi request reprint Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents
    Paul M Coplan
    Merck Research Laboratories, West Point, Pennsylvania, USA
    J Infect Dis 191:1427-34. 2005
    ..Therefore, we quantified the cross-clade reactivity, among unvaccinated individuals, of anti-HIV-1 T cell responses to the infecting HIV-1 clade relative to other major circulating clades...
  38. ncbi request reprint Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon
    Swati B Gupta
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Acquir Immune Defic Syndr 42:135-9. 2006
    ..Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples...
  39. ncbi request reprint Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion
    Gaetano Barbato
    Istituto di Ricerche di Biologia Molecolare P Angeletti IRBM, Via Pontina Km 30 600, 00040 Pomezia, Rome, Italy
    J Mol Biol 330:1101-15. 2003
    ..At the same time, our hypothesis offers a structural explanation for the mechanism of neutralization of mAb 2F5...
  40. ncbi request reprint Antigen burden is major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: potential implications for therapeutic immunization
    Lynda G Tussey
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Infect Dis 187:364-74. 2003
    ..Such assessments of the immune response may provide a refined measure of virus control...
  41. doi request reprint Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective
    Silvija I Staprans
    Merck Vaccines, West Point, Pennsylvania, USA
    Curr Opin HIV AIDS 5:377-85. 2010
    ..To consider how nonhuman primate (NHP) model systems can best contribute to HIV vaccine development...
  42. pmc Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene
    Danilo R Casimiro
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 76:185-94. 2002
    ..Thus, optimizing the immunogenic properties of HIV-1 Pol at the level of the gene sequence validates it as an antigen and provides an important step toward the construction of a potent pol-based HIV-1 vaccine component...
  43. doi request reprint Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development
    David C Kaslow
    Merck Research Laboratories, Merck and Co Inc, North Wales, Pennsylvania 19454, USA
    Annu Rev Med 62:201-15. 2011
    ..This review presents some emerging concepts that will likely shape efforts to develop active and passive immunization interventions in response to the reemergence of these bacterial pathogens...
  44. ncbi request reprint Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design
    Joseph G Joyce
    Department of Virus and Cell Biology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Biol Chem 277:45811-20. 2002
    ..We discuss these findings in terms of structural and immunological considerations as to the utility of a 2F5-like response...
  45. ncbi request reprint Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates
    Stefania Lamartina
    IRBM P Angeletti, Via Pontina Km 30, 600, 00040 Pomezia Rome, Italy
    Mol Ther 7:271-80. 2003
    ..Tight regulation of the gene encoding SEAP was demonstrated also in non-human primates. Notably, the system was induced in animals by Dox-dosing regimens comparable to those used in humans...
  46. ncbi request reprint Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunol 168:562-8. 2002
    ..These results demonstrate that bicistronic DNA vaccines containing GM-CSF elicit remarkably potent CD4(+) T cell responses and suggest that optimal Th cell priming requires the precise temporal and spatial codelivery of Ag and GM-CSF...
  47. pmc Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys
    Ramu A Subbramanian
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Research East RE 113, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 77:10113-8. 2003
    ..These studies suggest that multiepitope plasmid DNA vaccine-based prime-boost regimens can efficiently prime for CTL responses of increased breadth and magnitude, although they do not overcome predicted hierarchies of immunodominance...
  48. pmc Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
    ..These data suggest that although effector T cells can limit viral replication, they are not able to assist humoral immunity to prevent the establishment of initial infection...
  49. pmc Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques
    Adrian B McDermott
    Wisconsin National Primate Center, 1220 Capitol Court, Madison, WI 53715, USA
    J Virol 79:15556-66. 2005
    ..These results suggest that viral "breakthrough" in vaccinated animals and viral escape are not inextricably linked and underscore the need for additional research into the mechanisms of vaccine failure...
  50. ncbi request reprint Influence of peak viral load on the extent of CD4+ T-cell depletion in simian HIV infection
    Miles P Davenport
    Department of Haematology, Prince of Wales Hospital and Centre for Vascular Research, University of New South Wales, Kensington, New South Wales, Australia
    J Acquir Immune Defic Syndr 41:259-65. 2006
    ..Whether such a simple relation also holds for HIV or simian immunodeficiency virus infections remains to be determined, particularly in the gut and other anatomic sites in which most early T-cell depletion occurs...
  51. pmc Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239
    Nancy A Wilson
    Wisconsin National Primate Research Center, University of Wisconsin Madison, Madison, WI 53711, USA
    J Virol 80:5875-85. 2006
    ....
  52. pmc Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses
    Sampa Santra
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:11088-93. 2004
    ..This study, therefore, indicates that the steady-state memory, rather than the peak effector vaccine-elicited T lymphocyte responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine...
  53. pmc Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation
    Mark J Geels
    Department of Human Retrovirology, Academisch Medisch Centrum, Amsterdam, The Netherlands
    J Virol 79:11247-58. 2005
    ....
  54. pmc High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control
    Miles P Davenport
    Department of Haematology, Prince of Wales Hospital and Centre for Vascular Research, University of New South Wales, Kensington, Australia
    J Virol 79:10059-62. 2005
    ..Nevertheless, higher initial CD8(+) T-cell numbers were associated with reduced peak and chronic viral loads and reduced CD4(+) T-cell depletion...
  55. pmc Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor
    Elisabetta Bianchi
    Department of Molecular and Cell Biology, IRBM P Angeletti, Via Pontina Km 30 600, 00040 Pomezia Rome Italy
    J Virol 79:7380-8. 2005
    ..In addition, we present preliminary evidence that the approach can be extended to influenza A virus, although the equivalent HA(0) conjugate is not as efficacious as for influenza B virus...
  56. ncbi request reprint Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody
    Isaac J Krauss
    Laboratory for Bioorganic Chemistry, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10021, USA
    J Am Chem Soc 129:11042-4. 2007
  57. pmc Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination
    Arumugam Balamurugan
    Division of Infectious Diseases, 37 121 CHS, UCLA Medical Center, 10833 LeConte Ave, Los Angeles, CA 90095, USA
    J Virol 82:2784-91. 2008
    ....
  58. pmc Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual
    Mark J Geels
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Virol 77:12430-40. 2003
    ..These results demonstrate the sequential accumulation of CTL escape in a patient during disease progression, indicating that multiple combinations of T-cell epitopes are required to control viremia...
  59. doi request reprint Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
    Frances H Priddy
    Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Infect Dis 46:1769-81. 2008
    ....